My opinion, and also experience with a couple of other biotechs, is that there will be a significant re-rating on announcement of commencement (hard to predict a figure but maybe 50-100% rise). Then on conclusion of successful Ph II, who knows? A further 300%, 400%, 500%..... Then with buyout/partnering interest who knows? Anyone got any thoughts on exit points?
Hi and yes it should but it is the dosing and the responses that will do that (or not if we are unlucky).There were examples of pharmaceuticals announcing of starting the clinical trials and that alone has pushed the share prices up ,which subsequently have fallen back where they were or even lower.The good or excellent preliminary reports on the progress of patients almost always pushes significantly North the share price.In our case of VAL201 we should know relatively soon after the start if the patients with prostate cancer respond to it or not.I am not sure about 8 weeks a 12 weeks will be a minimum imo.Stach
I really think that MHRA Permit for VAL201 will not make much difference to the share price.What will make a huge difference will be a positive report on the initial progress of the patients that VAL will announce via RNS.It is a waste of time going on about it forever as it has not and will not make a slightest difference on the prices here.Stach
I wonder whether we could find some online sweepstake facility and run one on the timing of the MHRA green light? Obviously, the more enthusiastic amongst our number would be keen to bag this afternoon, Monday and Tuesday, whilst the more conservative and patient would pick dates into the start of August.
All proceeds to a prostate cancer charity (it would seem appropriate given the focus of VAL201).
Who'd be interested? I'm not going to go finding out if it's do-able if there's not interest.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.